Publications

ADT-1004: a first-in-class, oral pan-RAS inhibitor with robust antitumor activity in preclinical models of pancreatic ductal adenocarcinoma

Download PDF
Resource: ADT-1004: a first-in-class, oral pan-RAS inhibitor with robust antitumor activity in preclinical models of pancreatic ductal adenocarcinoma

.

Related Articles

The abscopal effect of IRE combined with anti–PD-1 achieves local ablation and systemic control of PDAC

Link

Multimodal Spatial Proteomic Profiling in Acute Myeloid Leukemia

Link